ASAN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Asana Inc. is not a strong buy for a beginner investor with a long-term horizon at this time. While there are some positive developments in AI-related revenue contributions, the overall financial performance, mixed analyst sentiment, and lack of clear trading signals suggest that holding off on investing is prudent. The stock's technical indicators and options data do not provide a compelling entry point.
The technical indicators show a mixed picture. The MACD is positive and expanding, which is a bullish sign, but the RSI is neutral at 44.91, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 6.327, with resistance at 6.678 and support at 5.976. This suggests limited upside potential in the short term.
AI Studio has reached $6M in annual recurring revenue with eight high-value customers.
AI Teammates beta launched with 200 customers and strong feedback, with AI expected to contribute 15% of new ARR this year.
Stabilization in net retention rate and sequential improvement in dollar-based retention rate.
Mixed Q4 results with a disappointing FY27 revenue outlook.
Declining net income (-48.29% YoY) and EPS (-48.15% YoY).
Short positions taken by influential market participants like Jackson, citing overvaluation and slowing organic growth.
Bearish moving averages and lack of significant insider or hedge fund activity.
In Q4 2026, revenue increased by 9.15% YoY to $205.57M, but net income dropped significantly by -48.29% YoY to -$32.21M. EPS also declined by -48.15% YoY to -$0.14, and gross margin fell slightly to 87.84% (-1.95% YoY). These metrics indicate growth challenges and profitability concerns.
Analyst sentiment is mixed. RBC upgraded the stock to Sector Perform with a $7 price target, citing strong feedback on AI products. However, several firms, including Morgan Stanley, Citi, and BofA, lowered price targets, reflecting concerns about decelerating growth, mixed Q4 results, and a disappointing FY27 outlook. Price targets range from $7 to $15, with ratings varying from Underperform to Buy.
